Lymphocyte activation gene 3 (LAG-3) serves as an immune checkpoint that attenuates T-cell activation. Antibodies targeting LAG-3, such as relatlimab, have the potential to enhance the activity of other checkpoint inhibitors when given in combination.

The Labcorp Oncology Medical Affairs team presented groundbreaking research during the American Society of Clinical Oncology (ASCO) annual meeting held June 2-6 in Chicago, Illinois.

Boston, MA

Convention Centre Dublin, Ireland